Opinion

Video

The Oral Systemic Space of Plaque Psoriasis

TJ Chao and Kristine Kucera, PA’s go into dept of the recent developments in the systemic oral space of plaque psoriasis.

Summary

In this series, dermatologists TJ Chao and Kristine Kucera delve into recent developments in plaque psoriasis treatment, including the emergence of TYK2 inhibitors. They highlight the evolving role of physician assistants in managing plaque psoriasis and discuss its recognition as a systemic disease. The conversation covers lab and monitoring requirements for TYK2 inhibitors like deucravacitinib, alongside a review of short- and long-term clinical trial data. Chao and Kucera offer insights into patient selection and the patient experience with oral systemic agents, providing guidance for selecting appropriate therapies in the expanding treatment landscape.

This summary was AI-generated and edited for clarity.

Related Videos
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
© 2024 MJH Life Sciences

All rights reserved.